Date: 2017-01-04
Type of information: Research agreement
Compound: customised synthetic promoters
Company: Synpromics (UK) GE Healthcare (USA - WI)
Therapeutic area: Technology - Services
Type agreement: research - R&D
Action mechanism: oligonucleotide
Disease:
Details:
- • On January 4, 2017, Synpromics announced a research collaboration with GE Healthcare to jointly develop customised synthetic promoters optimised for GE Healthcare’s proprietary biopharmaceutical manufacturing platform. Synpromics will develop a complex bar-coded library of synthetic promoters, using its proprietary PromPT™ platform, for extensive screening in GE Healthcare’s Chinese Hamster Ovary (CHO) - based expression system. The resulting characterised promoter toolbox is anticipated to have broad applicability for increasing the yield of a range of biopharmaceuticals, including proteins difficult to manufacture.
Financial terms:
- GE Healthcare is paying an upfront technology access fee and will have the rights to commercialise the improved platform.
Latest news:
Is general: Yes
